These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 31486872)

  • 1. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
    Shimada M; Yamaguchi H; Fukuda M; Tomono H; Honda N; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Takemoto S; Ikeda T; Nakatomi K; Nakamura Y; Nagashima S; Yamazaki T; Mukae H
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1059-1064. PubMed ID: 31486872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
    Fukuda M; Nakamura Y; Kasai T; Nagashima S; Nakatomi K; Doi S; Nakano H; Takatani H; Fukuda M; Kinoshita A; Soda H; Tsukamoto K; Oka M; Kohno S;
    J Thorac Oncol; 2009 Jun; 4(6):741-5. PubMed ID: 19404211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer.
    Fukuda M; Nakamura Y; Kinoshita A; Soejima Y; Yamaguchi H; Ikeda T; Izumikawa K; Takatani H; Fukuda M; Soda H; Hayashi N; Tsukamoto K; Oka M; Kohno S
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):645-51. PubMed ID: 23010852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-disease small cell lung cancer: protocol of ACIST study.
    Akagi K; Taniguchi H; Fukuda M; Yamazaki T; Ono S; Tomono H; Suyama T; Shimada M; Gyotoku H; Takemoto S; Yamaguchi H; Dotsu Y; Senju H; Soda H; Mizowaki T; Monzen Y; Ikeda T; Nagashima S; Tasaki Y; Nakamura D; Komiya K; Nakatomi K; Sasaki E; Hirakawa K; Mukae H
    Thorac Cancer; 2022 Aug; 13(16):2404-2409. PubMed ID: 35808894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer.
    Ohe Y; Negoro S; Matsui K; Nakagawa K; Sugiura T; Takada Y; Nishiwaki Y; Yokota S; Kawahara M; Saijo N; Fukuoka M; Ariyoshi Y
    Ann Oncol; 2005 Mar; 16(3):430-6. PubMed ID: 15653702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
    Ikeda T; Fukuda M; Nakamura Y; Kinoshita A; Senju H; Nakano H; Kitazaki T; Ogawara D; Taniguchi H; Motoshima K; Yamaguchi H; Nakatomi K; Shimada M; Nagashima S; Tsukamoto K; Kohno S;
    Cancer Chemother Pharmacol; 2014 Sep; 74(3):497-502. PubMed ID: 25034978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
    Kobayashi M; Matsui K; Iwamoto Y; Ebi N; Oizumi S; Takeda K; Sawa T; Shibata K; Saka H; Imamura F; Seki N; Saito H; Goto I; Nakagawa K;
    J Thorac Oncol; 2010 Jul; 5(7):1075-80. PubMed ID: 20479694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer.
    Inoue A; Yamazaki K; Maemondo M; Suzuki T; Kimura Y; Kanbe M; Isobe H; Nishimura M; Saijo Y; Nukiwa T
    J Thorac Oncol; 2006 Jul; 1(6):551-5. PubMed ID: 17409916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
    Sekine I; Harada H; Yamamoto N; Wakabayashi M; Murakami H; Goto K; Nogami N; Seto T; Oshita F; Okamoto H; Tanaka H; Tamura T; Ishikura S; Ohe Y
    Lung Cancer; 2017 Jun; 108():232-237. PubMed ID: 28625642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
    Okamoto K; Okamoto I; Takezawa K; Tachibana I; Fukuoka M; Nishimura Y; Nakagawa K
    Jpn J Clin Oncol; 2010 Jan; 40(1):54-9. PubMed ID: 19837690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer.
    Sun Y; Cheng Y; Hao X; Wang J; Hu C; Han B; Liu X; Zhang L; Wan H; Xia Z; Liu Y; Li W; Hou M; Zhang H; Xiu Q; Zhu Y; Feng J; Qin S; Luo X
    BMC Cancer; 2016 Apr; 16():265. PubMed ID: 27061082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
    Ettinger DS; Berkey BA; Abrams RA; Fontanesi J; Machtay M; Duncan PJ; Curran WJ; Movsas B; Byhardt RW;
    J Clin Oncol; 2005 Aug; 23(22):4991-8. PubMed ID: 15939930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of amrubicin hydrochloride and cisplatin in patients previously treated for advanced non-small cell lung cancer.
    Ikeda J; Maruyama R; Okamoto T; Shoji F; Wataya H; Ichinose Y
    Jpn J Clin Oncol; 2006 Jan; 36(1):12-6. PubMed ID: 16418184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose escalation and feasibility study of amrubicin combined with cisplatin in previously untreated patients with advanced non-small cell lung cancer.
    Yoshimura N; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Ichimaru Y; Hirata K; Kudoh S
    Am J Clin Oncol; 2013 Apr; 36(2):105-9. PubMed ID: 22270109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I/II trial of irinotecan plus amrubicin supported with G-CSF for extended small-cell lung cancer.
    Harada T; Hamada A; Shimokawa M; Takayama K; Kudoh S; Maeno K; Saeki S; Miyawaki H; Moriyama A; Nakagawa K; Nakanishi Y
    Jpn J Clin Oncol; 2014 Feb; 44(2):127-33. PubMed ID: 24379211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan and cisplatin with concurrent thoracic radiotherapy in a once-every-three-weeks schedule in patients with limited-disease small-cell lung cancer: a phase I study.
    de Jong WK; de Jonge MJ; van der Leest AH; van Meerbeeck JP; Groen HJ
    Lung Cancer; 2008 Jul; 61(1):123-8. PubMed ID: 18179842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
    Satouchi M; Kotani Y; Shibata T; Ando M; Nakagawa K; Yamamoto N; Ichinose Y; Ohe Y; Nishio M; Hida T; Takeda K; Kimura T; Minato K; Yokoyama A; Atagi S; Fukuda H; Tamura T; Saijo N
    J Clin Oncol; 2014 Apr; 32(12):1262-8. PubMed ID: 24638015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
    Asakuma M; Yamamoto M; Wada M; Ryuge S; Katono K; Yokoba M; Fukui T; Takakura A; Otani S; Maki S; Igawa S; Yanaihara T; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Masuda N
    Cancer Chemother Pharmacol; 2012 Jun; 69(6):1529-36. PubMed ID: 22415148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.